Migraines

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo.

More: continued here

Targeting a system which utilises peptides in the brain during a migraine could be the future of treatment for this debilitating condition. The future and recent developments in the field of migraine are discussed in a Comment in this week’s edition of The Lancet, written by Dr Stephen D Silberstein, Thomas Jefferson University, Philadelphia, PA, USA.

More: continued here

New research unveiled at TCT 2008 by Dr. Stephen Silberstein (a leading neurologist) suggests that 66 percent of chronic migraine sufferers have abnormal blood flow caused by a hole in their heart or a right-to-left shunt that bypasses the filtration process of the lungs. Most of these defects are known as a PFO, a heart condition prior research shows is found in 25 percent of the population.

More: continued here

Migraines can be a debilitating condition and affect around 15% of the UK population, over 70% of whom are women. Recent research undertaken by Imigran Recovery reveals that over 81% of migraine sufferers cannot always control their migraine attacks while 71% say migraines leave them unable to function. For the 81% who are unable to control their migraines, a new interactive tool www.migraineactionplan.co.uk has been developed.

More: continued here

A novel therapy using a miniature nerve stimulator instead of medication for the treatment of profoundly disabling headache disorders improved the experience of pain by 80-95 percent, according to a new study from the University of California, San Francisco and the National Hospital for Neurology and Neurosurgery in London.

More: continued here